John Borders, MD
Internal Medicine · Lexington, KYNPI 1962401026
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 502 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 502 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$834
- Pfizer$705
- Lilly USA, LLC$581
- Novartis$516
- Amgen$506
- AbbVie$432
- plus $5K from 46 others
Across 17 payments — averaging $9296.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$135K
- Sanofi US Services Inc.$23K
What the payments were for
- Speaking & faculty fees$260%
- Food & beverage$8,05698%
- Education$1552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,236 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 117 | $147,692 |
| EliquisApixaban | 126 | $139,499 |
| TrulicityDulaglutide | 88 | $112,214 |
| MounjaroTirzepatide | 107 | $111,561 |
| JardianceEmpagliflozin | 77 | $96,837 |
| WegovySemaglutide | 49 | $66,059 |
| XareltoRivaroxaban | 28 | $45,458 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 42 | $32,357 |
| GemtesaVibegron | 34 | $27,508 |
| TrulancePlecanatide | 17 | $24,691 |
| EntrestoSacubitril/Valsartan | 23 | $23,495 |
| Rosuvastatin Calcium | 1,140 | $18,368 |
| BelsomraSuvorexant | 33 | $17,288 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $17,041 |
| MyrbetriqMirabegron | 25 | $15,989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $581 | $223,775195 claims |
| Novo NordiskOzempic, Wegovy | $834 | $213,751166 claims |
| PfizerEliquis, Premarin | $705 | $145,138137 claims |
| Boehringer IngelheimJardiance | $253 | $96,83777 claims |
| Johnson & JohnsonXarelto | $127 | $45,45828 claims |
| AstraZenecaBreztri Aerosphere | $166 | $32,35742 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $432 | $29,34576 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $231 | $27,50834 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $116 | $24,69117 claims |
| NovartisEntresto | $516 | $23,49523 claims |
| MerckBelsomra | $100 | $17,28833 claims |
| Astellas Pharma US IncMyrbetriq | $362 | $15,98925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Lexington
- David ManninoLexington$168K
- Fadi BachaLexington$31K
- Jad BalloutLexington$30K
- Thomas von UnrugLexington$22K
- Danilo CoralesLexington$17K
- Mohamed TashaniLexington$17K
- Kelli TrentLexington$16K
- Richard BeltLexington$14K
- Coutney SchniedersLexington$12K
- Fares KhaterWhitesburg$412K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.